DiaMedica Therapeutics (DMAC) CEO receives 60,200 RSU award vesting over four years

Rhea-AI Filing Summary

Pauls Dietrich John reported acquisition or exercise transactions in this Form 4 filing.

DiaMedica Therapeutics Inc. reported that President & CEO Dietrich John Pauls received a grant of 60,200 restricted stock units (RSUs) of voting common shares at no stated per-share cost. These RSUs vest in four equal annual installments on the first through fourth anniversaries of the grant date, contingent on continued service. Following this award, Pauls holds 128,791 voting common shares, including 1,749 shares issuable upon settlement of deferred share units granted under the company’s Deferred Share Unit Plan.

Insider Trade Summary

Net Buyer: 60,200 shares

Net Buy 1 txn

Insider Pauls Dietrich John

Role President & CEO

Type	Security	Shares	Price	Value
Grant/Award	Voting Common Shares, no par value per share F1, F2	60,200	$0.00	$0.00

Holdings After Transaction: Voting Common Shares, no par value per share — 128,791 shares (Direct)

Footnotes (2)

1. F1. The restricted stock units will vest in four equal installments, each on the first, second, third, and fourth anniversaries of the grant date, provided, however, that the participant remains continuously employed by or provides services to the Company, or one of its Subsidiaries or Affiliates, through the applicable vesting date.
2. F2. Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan.

Key Figures

RSUs granted: 60,200 shares Shares after transaction: 128,791 shares Deferred share unit component: 1,749 shares +2 more

5 metrics

RSUs granted 60,200 shares Restricted stock units of voting common shares granted to President & CEO

Shares after transaction 128,791 shares Total voting common shares beneficially owned after the award

Deferred share unit component 1,749 shares Voting common shares issuable upon settlement of deferred share units included in total

Per-share transaction price $0.0000 Reported price for the RSU grant transaction

Vesting schedule 4 installments RSUs vest in four equal annual installments over four years

Key Terms

restricted stock units, deferred share units, vest, grant date

4 terms

restricted stock units financial

"The restricted stock units will vest in four equal installments, each on the first,"

Restricted stock units are a type of company reward where employees are promised shares of stock, but they only fully own these shares after meeting certain conditions, like staying with the company for a set time. They matter because they can become valuable assets and are often used to motivate employees to help the company succeed.

deferred share units financial

"Includes 1,749 voting common shares issuable upon settlement of deferred share units"

Deferred share units are promises that give an executive or director the right to receive company shares or their cash value at a future date, often when they retire or leave the company. Think of them as a paycheck held in a savings account that converts into stock later; they matter to investors because they tie pay to long-term performance, create potential future dilution of shares, and represent a delayed cash or share obligation the company must eventually fulfill.

vest financial

"The restricted stock units will vest in four equal installments, each on the first,"

A vest is the process by which an employee earns the right to receive certain benefits or ownership interests, such as stock or retirement funds, over time. It’s similar to earning a reward gradually, ensuring that the benefit becomes fully yours only after a set period or meeting specific conditions. This makes it important for investors because it determines when they can actually claim or use those benefits.

grant date financial

"installments, each on the first, second, third, and fourth anniversaries of the grant date,"

The grant date is the day a company formally gives an employee or contractor the right to receive stock-based compensation, such as stock options or restricted shares. It matters to investors because it fixes key terms—like the price, the start of the ownership clock, and when the award will affect the company’s financial statements and share count—so it can influence dilution, reported expenses, and potential future selling pressure.

FAQ

What did DiaMedica Therapeutics (DMAC) disclose about insider equity awards?

DiaMedica Therapeutics disclosed that its President & CEO Dietrich John Pauls received a grant of 60,200 restricted stock units of voting common shares, vesting over four years subject to his continued employment or service.

How many DiaMedica Therapeutics (DMAC) shares does the CEO hold after this Form 4?

After the reported award, President & CEO Dietrich John Pauls beneficially holds 128,791 voting common shares, which includes 1,749 shares issuable upon settlement of deferred share units previously granted.

What are the vesting terms of the 60,200 RSUs granted by DMAC?

The 60,200 restricted stock units granted to DiaMedica’s CEO vest in four equal installments on the first, second, third, and fourth anniversaries of the grant date, conditioned on continued employment or service to the company or its affiliates.

Did the DiaMedica (DMAC) CEO purchase these shares on the market?

No. The filing shows a Form 4 transaction coded “A” for grant, award, or other acquisition, with a per-share transaction price of $0.0000, indicating a compensatory equity award rather than an open-market purchase.

Are any DiaMedica (DMAC) CEO holdings tied to deferred share units?

Yes. The CEO’s post-transaction total of 128,791 voting common shares includes 1,749 shares issuable upon settlement of deferred share units previously granted under DiaMedica Therapeutics Inc.’s Deferred Share Unit Plan.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Form 4 Insider Transactions: What Each Field Means →

Available on EDGAR 08/12/2026 - 04:24 PM Accepted by SEC EDGAR 08/12/2026 - 04:23 PM Learn about SEC filing dates

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Pauls Dietrich John

(Last) (First) (Middle)

301 CARLSON PARKWAY

SUITE 210

(Street)

MINNEAPOLIS MINNESOTA 55305

(City) (State) (Zip)

UNITED STATES

(Country)

2. Issuer Name and Ticker or Trading Symbol
DiaMedica Therapeutics Inc. [ DMAC ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

X	Director		10% Owner
X	Officer (give title below)		Other (specify below)
	President & CEO

2a. Foreign Trading Symbol

3. Date of Earliest Transaction (Month/Day/Year)
08/10/2026

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

4. If Amendment, Date of Original Filed (Month/Day/Year)

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Voting Common Shares, no par value per share	08/10/2026		A		60,200(1)	A	$0	128,791(2)	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares

Explanation of Responses:

1. The restricted stock units will vest in four equal installments, each on the first, second, third, and fourth anniversaries of the grant date, provided, however, that the participant remains continuously employed by or provides services to the Company, or one of its Subsidiaries or Affiliates, through the applicable vesting date.

2. Includes 1,749 voting common shares issuable upon settlement of deferred share units granted under the DiaMedica Therapeutics Inc. Deferred Share Unit Plan.

	/s/ Joshua L. Colburn, attorney-in-fact	08/12/2026
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.
* Form 4: SEC 1474 (03-26)